TY - JOUR
T1 - Doxorubicin-docetaxel sequential schedule
T2 - Results of front-line treatment in advanced breast cancer
AU - Palmeri, S.
AU - Leonardi, V.
AU - Tamburo De Bella, M.
AU - Morabito, A.
AU - Vaglica, M.
AU - Accurso, V.
AU - Ferraù, F.
AU - Failla, G.
AU - Agostara, B.
AU - Massidda, B.
AU - Valenza, R.
AU - Fanelli, M.
AU - Gasparini, Giampietro
PY - 2002
Y1 - 2002
N2 - Objective: We conducted a multi-institutional phase II study to evaluate the tolerability and activity of a sequential schedule of treatment with doxorubicin and docetaxel in chemotherapy-naive women with advanced breast cancer. Methods: A total of 73 patients with PS (ECOG) 0-2, aged 2 by intravenous (i.v.) 30 min injection on day 1 followed the day after by docetaxel 75 mg/m2, by i.v. 60 min infusion. Cycles were repeated every 28 days. Results: Overall, the median number of administered cycles was 6 (range 1-14). The most common toxicity was hematological, with 56.2% of the patients who experienced grade 3-4 neutropenia. However, febrile neutropenia occurred only in 2.8% of the cases. The median cumulative dose of doxorubicin was 350 mg/m2 (range 50-700 mg/m2). Eleven patients (15.4%) were documented to have >10% but
AB - Objective: We conducted a multi-institutional phase II study to evaluate the tolerability and activity of a sequential schedule of treatment with doxorubicin and docetaxel in chemotherapy-naive women with advanced breast cancer. Methods: A total of 73 patients with PS (ECOG) 0-2, aged 2 by intravenous (i.v.) 30 min injection on day 1 followed the day after by docetaxel 75 mg/m2, by i.v. 60 min infusion. Cycles were repeated every 28 days. Results: Overall, the median number of administered cycles was 6 (range 1-14). The most common toxicity was hematological, with 56.2% of the patients who experienced grade 3-4 neutropenia. However, febrile neutropenia occurred only in 2.8% of the cases. The median cumulative dose of doxorubicin was 350 mg/m2 (range 50-700 mg/m2). Eleven patients (15.4%) were documented to have >10% but
KW - Advanced breast cancer
KW - Docetaxel
KW - Doxorubicin
KW - Phase II trial
UR - http://www.scopus.com/inward/record.url?scp=0036970051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036970051&partnerID=8YFLogxK
U2 - 10.1159/000065466
DO - 10.1159/000065466
M3 - Article
C2 - 12381898
AN - SCOPUS:0036970051
SN - 0030-2414
VL - 63
SP - 205
EP - 212
JO - Oncology
JF - Oncology
IS - 3
ER -